Vita Life Sciences (ASX:VLS) Growth Rank: 7 (As of Jul. 11, 2026) — 17% Above Median


ASX:VLS Vita Life Sciences Ltd ASX:VLS
92 GF Score
Price A$2.50
GF Value A$2.48
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vita Life Sciences Growth Rank?

Vita Life Sciences ASX:VLS +1.21% 92 Growth Rank is 7 as of Jul. 11, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates ASX:VLS with a GF Score™ of 92/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review.

Vita Life Sciences has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Vita Life Sciences Growth Rank Related Terms

ASX:VLS vs ZTS, UTHR: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vita Life Sciences Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Growth Rank distribution charts can be found below:

* The bar in red indicates where Vita Life Sciences's Growth Rank falls into.


ASX:VLS
92GF Score
Vita Life Sciences Ltd ASX:VLS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Vita Life Sciences (ASX:VLS) has a Growth Rank of 7 as of Jul. 11, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Vita Life Sciences and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Vita Life Sciences' Growth Rank has ranged from 3.00 to 9.00.
Is Vita Life Sciences' Growth Rank too high?
Vita Life Sciences' current Growth Rank of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. Overall, Vita Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Growth Rank compare to ZTS and UTHR?
Vita Life Sciences' Growth Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Vita Life Sciences' own Growth Rank has ranged from 3.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Vita Life Sciences and its competitors. Vita Life Sciences's current Growth Rank is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current Growth Rank is 7, which is 17% above median its 10-year median of 6.00. Vita Life Sciences' overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Growth Rank is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?

Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued. The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48. GuruFocus considers Vita Life Sciences to be Fairly Valued.

Key valuation signals for ASX:VLS:

  • Growth Rank: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vita Life Sciences Business Description

Address 1-5 Chalmers Crescent, Suite 802, Level 8, Mascot, Sydney, NSW, AUS, 2020
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
92GF Score

Get the complete analysis for ASX:VLS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.50
Price
A$2.48
GF Value